 The development of NSAIDs iNOS inhibitor hybrids is a new strategy for the treatment of inflammatory diseases by suppression of the overproduction of PGE

@highlight A novel series of aryl carboximidamides
@highlight and their cyclized 3 aryl 1 2 4 oxadiazoles
@highlight counterparts derived from indomethacin
@highlight were designed and synthesized.
@highlight Compound
@highlight and
@highlight proved to be the most potent anti inflammatory agents.
@highlight Compounds
@highlight and
@highlight possessed the lowest ulcerogenic liabilities.
@highlight A strong correlation between the
@highlight iNOS inhibitory activities of
@highlight and
@highlight and docking study has been established.
